Safety and Efficacy Study in Patients With Major Depressive Disorder

NCT00896363 | Completed Phase 2 Results

• 1 other identifier: 109035
• Study Type: interventional
• Target: 99
• Locations: 1 country
• Sites: 15

Brief Summary

The purpose of this study is to test if GSK163090 can reduce the symptoms of depression. The safety and how well the body can handle the drug will also be investigated. The study will be conducted in Russia in hospitalised patients with severe depression. GSK163090 will be compared with placebo, which looks like the study drug but does not contain any active substance. Subjects will be given either the study drug or the matching placebo.

Conditions

Depressive Disorder

Keywords

anti-depressant; Severe Depression; Efficacy; Major Depressive Disorder; Major Depressive Episode

Outcome Measures

Primary Outcomes (13)

• Change From Baseline in the Hamilton Depression Rating Scale (HAMD17), on Day 14 and 42

  HAMD-17 is a 17-item scale that evaluates depressed mood, vegetative and cognitive symptoms of depression, and co-morbid anxiety symptoms. The 17 items were rated on either a 5-point (0-4) or a 3-point (0-2) scale. In general, the 5 point scale items use a rating of 0=absent; 1=doubtful to mild; 2=mild to moderate; 3=moderate to severe; 4=very severe. The 3-point scale items use a rating of 0=absent; 1=probable or mild; 2=definite. The total HAMD-17score ranges from 0 (not ill) to 52 (severely ill). The highest possible score was 52, which represented the most severe measure of depression; the lowest possible score was 0, which represents an absence of depression. Baseline was defined as the assessment done on Day 1 (pre-dose). Change from baseline in total Score was the difference between HAMD total score at the time point being analyzed to Day 1.

  Baseline (Day 1, pre-dose), Day 14 and Day 42

• Change From Baseline in Bech Melancholia Subscale (BECH 6) Scale, on Day 14 and 42

  The bech melancholia is sum of scores on 6 items- depressed mood, feelings of guilt, work and activities, retardation, anxiety psychic, somatic symptoms general (items 1, 2, 7, 8, 10 and 13 respectively). Each item having 5 responses. The items are rated on a scale of 0-4, where 0=absent; 1=doubtful to mild; 2=mild to moderate; 3=moderate to severe; 4=very severe. Total possible score is 0-24. where the lowest possible score was 0, which represented an absence of depression and higher scores reflecting greater severity of diseases. Baseline was defined as the assessment done on Day 1. Change from baseline was the difference between BECH 6 scale at the time point being analyzed to randomization.

  Baseline (Day 1, pre-dose), Day 14 and Day 42

• Change From Baseline in Quick Inventory of Depressive Symtomatology - Self Rated (QIDS-SR) Scale, on Day 14 and 42

  The QIDS-SR is a 16-item, participant-rated short form of the Inventory of Depressive Symptomatology that assesses 9 domains: sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle, and late insomnia or hypersomnia), appetite/weight increase/decrease and psychomotor agitation/retardation. A total score was obtained by summing scores on each domain. the scores ranges from 0 (none) to 27 (very severe), where the highest possible score was 27, which represented the most severe measure of depression; the lowest possible score was 0, which represents an absence of depression. Baseline was defined as the assessment done on Day 1. Change from Randomization in total score was the difference between QIDS total score at the time point being analyzed to randomization.

  Baseline (Day 1, pre-dose), Day 14 and Day 42

• Number of Participants With Suicidal Behavior and Suicidal Ideation Subscales of the Columbia Suicide Severity Rating Scale (C-SSRS)

  The C-SSRS was a clinician-rated scale that evaluated severity and change of suicidality by integrating both behaviour and ideation. The 2 of 3 sections of the scale were suicidal behavior and suicidal ideation. For suicidal behaviour participants were scored as non-suicidal-0, preparatory acts or behavior communicating ideation-01, aborted attempt-2, interrupted attempt-3 or actual attempt-4. The score ranges from 0-4, where 0 was absence of suicidal behavior and 4 being the most severe form of suicidal behavior. On the Suicidal Ideation scale, participants were scored as non-suicidal-0, wish to be dead-1, non-specific active suicidal thoughts-2, active suicidal ideation with associated thoughts of methods without intent-3, active suicidal ideation with some intent to act on suicidal thoughts without clear plan-4, active suicidal ideation with plan and intent-5. The score ranges from 0-5, where 0 was absence of suicidal ideation and 5 being the most severe form of suicidal ideation.

  Up to Day 52

• Number of Participants With Abnormal Hematology Values of Clinical Concern Range (CCR).

  Only those parameters for which at least one value of CC was reported were summarized. Pre-defined limits of CC (CC Low \[relative to the lower limit of normal\], CC High \[relative to the upper limit of normal\]) were: hemoglobin (Hb): \> 25, 180; hematocrit (Hct): \> 0.075, 0.54; absolute neutrophil count (ANC): \< 1.5, NA; platelet: \< 100, \> 550; white blood cells (WBC): \< 3,\> 20

  Up to Day 42

• Number of Participants With Abnormal Chemistry Values of CCR

  Only those parameters for which at least one value of CC was reported were summarized. Pre-defined limits of CC (CC Low \[relative to the lower limit of normal\], CC High \[relative to the upper limit of normal\]) were: albumin (unit: gram per liter): \< 30, NA; alanine aminotransferase (ALT): NA, \>= 3 times upper limit of normal; aspartate aminotransferase (AST): NA, \>= 3 times upper limit of normal; total bilirubin: NA, \>=1.5 times upper limit of normal; calcium: \< 2.0, \> 2.75; gamma glutamyl transferase (GGT): \< 3.0, \> 9; potassium: \< 3.0, \> 5.5; magnesium: \< 0.5, \> 1.23.

  Up to Day 42

• Change From Baseline in Liver Chemistry -Alkaline Phosphatase (ALP), ALT, AST and GGT

  Clinical liver chemistry parameters of Alkaline Phosphatase , ALT, AST, GGT were assessed on screening, Day 7, Day 14, Day 28 and Day 42. Screening was defined as Baseline. Change from Baseline in liver chemistry was the difference between the value at time point analyzed and screening.

  Baseline (screening) up to Day 42

• Change From Baseline in Liver Chemistry- Direct Bilirubin and Total Bilirubin

  Liver chemistry parameters: Direct Bilirubin and Total Bilirubin were assessed on screening, Day 7, Day 14, Day 28 and Day 42. Screening was defined as Baseline. Change from Baseline in liver chemistry was the difference between the value at time point analyzed and screening.

  Baseline (screening) up to Day 42

• Number of Participant of Urinanalysis Assessment Over Period

  Urinalysis parameters included: Urine Occult Blood, Urine Ketones, Urine Ketones. data for number of participants with abnormal urinanalysis parameters was reported by dipstick method. dipstick was a strip used to detect the presence or absence of these parameters in the urine sample. dipstick test gives results in a semi-quantitative manner, and results can be read as negative, Trace, 1+, 2+, and 3+, indicating proportional concentrations in the urine sample. Urine occult blood dipstick and urine general dipstick were semi quantitative results. Urine glucose and urine ketones dipstick results were in milimole per liter, urine protein dipstick results were in gram per liter.

  Screening (Day -10 to -2), Day 14 and Day 42

• Change From Baseline in Electrocardiogram (ECG) Values -PR Interval, QRS Duration, QT Interval, QTcB, QTcF, RR Interval

  Data for change from Baseline was reported for PR Interval, QRS Duration, QT Interval, QTcB, QTcF, and RR Interval. 12-lead ECGs was obtained at each time point during the study using an ECG machine that automatically calculated the heart rate and measures PR, QRS, QT, and QTcB ,QTcF, and RR intervals. Day -1 evening (PM) was the Baseline for participants with only Day -1 records. Day 1 PM Dose was the Baseline for participants with Day 1 records. Baseline was the mean of replicate assessments. Change from Baseline was the difference between the value at the time point analyzed and baseline value.

  Baseline (Day 1) and up to Day 42

• Mean of Change From Baseline in Systolic and Diastolic Blood Pressure (BP)

  Semi-supine systolic and diastolic blood pressure was assessed at the specified time points. Measurements were taken after the participant has been semi-supine for at least 5 minutes. BP was measured at least every hour until the values were within the normal range. Day 1 was Baseline and change from Baseline was difference between the value at the time point analyzed and baseline value.

  Baseline (Day 1) , Day 2, 3, 4, 5, 6, 7, 8, 14, 21, 28 and 42

• Mean of Change From Baseline in Heart Rate

  Heart rate is the speed of the heartbeat measured by the number of contractions of the heart per minute, (beats per minute). Heart rate was assessed at the specified time points. Measurements were taken after the participant has been semi-supine for at least 5 minutes. Day 1 was Baseline and change from Baseline was difference between the value at the time point analyzed and baseline value.

  Baseline (Day 1), Day 2, 3, 4, 5, 6, 7, 8, 14, 21, 28 and 42

• Number of Participants With All Adverse Events (AEs), and Serious Adverse Events (SAEs)

  Data for number of participants who presented one or more adverse events (serious or non serious) was reported. An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.

  Up to Day 52

Secondary Outcomes (4)

• Mean Last Observed Quantifiable Concentration (Ct) of GSK163090 Over the Period

  Day 4 (AM pre-dose), Day 7 (AM and PM pre-dose), Day 10 (AM and PM pre-dose), Day 14 (AM and PM pre-dose), Day 21 (AM pre dose), Day 28 (AM pre dose), Day 42 (AM pre-dose and 4-6 h post AM dose)

• Area Under Concentration-time Curve (AUC) at Steady State

  Day 4 (AM pre-dose), Day 7 (AM and PM pre-dose), Day 10 (AM and PM pre-dose), Day 14 (AM and PM pre-dose), Day 21 (AM pre dose), Day 28 (AM pre dose), Day 42 (AM pre-dose and 4-6 h post AM dose)

• Average Concentration (Cave) at Steady State

  Day 4 (AM pre-dose), Day 7 (AM and PM pre-dose), Day 10 (AM and PM pre-dose), Day 14 (AM and PM pre-dose), Day 21 (AM pre dose), Day 28 (AM pre dose), Day 42 (AM pre-dose and 4-6 h post AM dose)

• Preliminary Pharmacokinetic/ Pharmacodynamic (PK/PD)Relationships for GSK163090 in Participants With MDD.

  Day 4 (AM pre-dose), Day 7 (AM and PM pre-dose), Day 10 (AM and PM pre-dose), Day 14 (AM and PM pre-dose), Day 21 (AM pre dose), Day 28 (AM pre dose), Day 42 (AM pre-dose and 4-6 h post AM dose)

Study Arms (2)

Active

ACTIVE COMPARATOR

Parallel Group - High Dose Arm, Low Dose Arm

Drug: GSK163090 1 mg; Drug: GSK163090 3 mg

Placebo

PLACEBO COMPARATOR

Parallel Group

Drug: GSK163090 Placebo

Interventions

GSK163090 1 mg DRUG

Developed for the treatment of Major Depressive Disorder

Active

GSK163090 Placebo DRUG

Developed for the treatment of Major Depressive Disorder

Placebo

GSK163090 3 mg DRUG

Developed for the treatment of Major Depressive Disorder

Active

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Currently have severe depression (Major Depressive Disorder - without psychotic features)
• meet criteria (DSM IV-TR ) for current major depressive episode for at least 4 weeks but for no greater than 24 months
• depression questionnaire (HAMD17) total score greater than or equal to 24
• subject must read and able to give written informed consent
• male or female 18 to 64 years
• use appropriate birth control method
• BMI 18.8 - 35.0 kg/m2 (inclusive)

You may not qualify if:

• Primary diagnosis of other psychiatric disorders
• thoughts of killing ones self or someone else
• taking psychiatric medicine or therapy within the six months
• Has previously failed an adequate course of medication for MDD from two different classes of antidepressants.
• Unstable medical disorder or a disorder that would interfere with the action of the drug
• Abuse of alcohol or drugs
• Past history of serotonin syndrome or a history of clinical significant intolerance of SSRIs (class of drugs used for depression).
• History of migraine headaches that respond to treatment with triptan medication.
• History of a clinically significant abnormality of the neurological system (including dementia and other cognitive disorders or significant head injury) or any history of seizure (excluding febrile seizure).
• Currently taking part in another clinical study or has done so within six months
• Pregnant, planning to become pregnant shortly or breastfeeding
• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (15)

GSK Investigational Site

Kemerovo, 650036, Russia

Location

GSK Investigational Site

Lipetsk Region, 399083, Russia

Location

GSK Investigational Site

Moscow, 119992, Russia

Location

GSK Investigational Site

Nizhny Novgorod, 603107, Russia

Location

GSK Investigational Site

Saint Petersburg, 190005, Russia

Location

GSK Investigational Site

Saint Petersburg, 190121, Russia

Location

GSK Investigational Site

Saint Petersburg, 191180, Russia

Location

GSK Investigational Site

Saint Petersburg, 193167, Russia

Location

GSK Investigational Site

Saint Petersburg, 194044, Russia

Location

GSK Investigational Site

Saint Petersburg, 197341, Russia

Location

GSK Investigational Site

Saint Petersburg, Russia

Location

GSK Investigational Site

Saratov, 410060, Russia

Location

GSK Investigational Site

Smolensk, 214 019, Russia

Location

GSK Investigational Site

Tomsk, 634014, Russia

Location

GSK Investigational Site

Yekaterinburg, 620030, Russia

Location

Related Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

MeSH Terms

Conditions

Depressive Disorder; Depression; Depressive Disorder, Major

Interventions

1-(3-(2-(4-(2-methyl-5-quinolinyl)-1-piperazinyl)ethyl)phenyl)-2-imidazolidinone

Condition Hierarchy (Ancestors)

Mood Disorders; Mental Disorders; Behavioral Symptoms; Behavior

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 7, 2009
• First Posted: May 11, 2009
• Study Start: April 23, 2009
• Primary Completion: February 9, 2010
• Study Completion: February 9, 2010
• Last Updated: March 19, 2018
• Results First Posted: March 19, 2018

Record last verified: 2017-08

Data Sharing

• IPD Sharing: Will share

Locations

RU (15)